XBiotech Inc.
XBiotech Inc. (XBIT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
xbit · stock forecast · 3 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Buy
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $2.37
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $2.34 | ↓ 1.18% |
1-day model range: $2.34–$2.35. Peak: $2.35 (-1.18%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $2 | -32.8% |
| 2028 | $1 | -43.8% |
| 2029 | $1 | -48.5% |
| 2030 | $1 | -50.6% |
| 2031 | — | -51.6% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · XBIT · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2020-04-07 | Piper Sandler | Maintains | Overweight→Overweight |
| 2019-12-11 | PiperJaffray | Maintains | Overweight→Overweight |
| 2019-12-11 | Piper Sandler | Maintains | Overweight→Overweight |
| 2019-06-14 | Piper Sandler | Maintains | Overweight→Overweight |
| 2019-06-14 | Piper Jaffray | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on XBiotech Inc. (XBIT) stock. Of the recent 5 rating actions, 0 were upgrades and 0 were downgrades. 3 analysts currently cover XBIT.
Analyst Recommendation Trends
XBIT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$28M
↓ 81.3% YoY
Revenue Next Year
$28M
↑ 0.0% YoY
EPS This Year
$0.19
EPS Next Year
$0.13
↓ 31.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast XBIT EPS of $0.19 for the current fiscal year, based on estimates from 1 analysts. The XBIT revenue forecast is $28M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The XBIT stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus XBIT price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The XBIT short-term stock prediction for tomorrow is $2.34 (-1.18%). The XBIT stock price prediction for 2027 estimates an average of $2. The XBIT stock prediction for 2030 projects a range of $1–$1.
XBiotech Inc. trades on NASDAQ under the ticker XBIT. The XBIT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
XBIT forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month XBIT price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $2.37.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.